Jugessur A, Frost P, Andersen T I, Steine S, Lindblom A, Børresen-Dale A L, Eiken H G
Center for Molecular Medicine, Haukeland University Hospital, Bergen, Norway.
J Mol Med (Berl). 2000;78(10):580-7. doi: 10.1007/s001090000147.
A novel approach to mutation screening in the large exon 11 (comprising 3427 bp) of the human BRCA1 gene is presented. Restriction endonuclease fingerprinting single-strand conformation polymorphism (REF-SSCP) is based on repeated detection of DNA sequence variants in different restriction endonuclease fragments, and we evaluated the method using blood samples from 25 Norwegian patients with hereditary breast/ovarian cancer. We compared REF-SSCP to constant denaturant gel electrophoresis (CDGE) and to the protein truncation test (PTT). REF-SSCP detected 12 different DNA variants. Four of these were not detected by CDGE, and only one variant detected by CDGE was missed by REF-SSCP. PTT detected 4 of these 13 variants. REF-SSCP was subsequently applied to a second patient series (Swedish, n=20). A total of 14 different DNA variants were detected by REF-SSCP, 6 of which were truncating mutations (PTT detected only 4). Nonsense and frameshift mutations that are putative breast/ovarian cancer mutations, were detected in 7 of the 25 Norwegian and 9 of the 20 Swedish patients.
本文介绍了一种用于人类BRCA1基因第11大外显子(包含3427bp)突变筛查的新方法。限制性内切酶指纹单链构象多态性(REF-SSCP)基于对不同限制性内切酶片段中DNA序列变异的重复检测,我们使用来自25名挪威遗传性乳腺癌/卵巢癌患者的血样对该方法进行了评估。我们将REF-SSCP与恒定变性剂凝胶电泳(CDGE)以及蛋白质截短试验(PTT)进行了比较。REF-SSCP检测到12种不同的DNA变异。其中4种未被CDGE检测到,而CDGE检测到的只有1种变异REF-SSCP未检测到。PTT检测到了这13种变异中的4种。REF-SSCP随后应用于第二个患者系列(瑞典人,n=20)。REF-SSCP总共检测到14种不同的DNA变异,其中6种是截短突变(PTT仅检测到4种)。在25名挪威患者中的7名以及20名瑞典患者中的9名中检测到了可能是乳腺癌/卵巢癌突变的无义突变和移码突变。